Key Insights

Highlights

Success Rate

69% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

23.8%

5 terminated out of 21 trials

Success Rate

68.8%

-17.8% vs benchmark

Late-Stage Pipeline

29%

6 trials in Phase 3/4

Results Transparency

82%

9 of 11 completed with results

Key Signals

9 with results69% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (1)
P 2 (7)
P 3 (5)
P 4 (1)

Trial Status

Completed11
Terminated5
Recruiting4
Unknown1

Trial Success Rate

68.8%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07552454Not ApplicableRecruitingPrimary

Picankibart in Palmoplantar Pustulosis

NCT07219420Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT05994976Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

NCT07013201Phase 2RecruitingPrimary

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07000630Not ApplicableTerminatedPrimary

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

NCT07428915Completed

Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

NCT04459507CompletedPrimary

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

NCT05710185Phase 4TerminatedPrimary

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT04493424Phase 2TerminatedPrimary

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

NCT03633396Phase 2CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

NCT05174065Phase 3CompletedPrimary

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

NCT02641730Phase 3CompletedPrimary

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

NCT05194839Phase 2TerminatedPrimary

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT03972280Phase 1Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

NCT04061252Phase 3CompletedPrimary

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

NCT03988335Phase 2CompletedPrimary

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT04572997Phase 2CompletedPrimary

Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)

NCT01794117Phase 2Completed

Anakinra for Inflammatory Pustular Skin Diseases

NCT04566471UnknownPrimary

Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence

NCT01780857CompletedPrimary

Immune Signature of Palmoplantar Pustulosis

Scroll to load more

Research Network

Activity Timeline